Onico Medical Completes Angel Funding Round, Driving Aesthetic Medicine Advancement with Innovative Energy-Based Technologies
Recently, Shanghai Ounico Medical Technology Co., Ltd. completed its angel round of financing. The investor in this round was Huayi Capital, which specializes in quantitative investment in the healthcare and life sciences sector. Following the completion of the financing, Ounico Medical will further enhance the technical applications of its energy platform.
Shanghai Ounico Medical Technology Co., Ltd. was established in December 2023. Its core team hails from the field of serious medical care, and has incorporated professionals with extensive experience in medical aesthetics development. The company is positioned to develop high-end active medical devices, leveraging technological platforms such as pulsed field ablation, non-focused ultrasound ablation, phased-array ultrasound, radiofrequency, and microwave. It innovatively applies novel energy sources to medical aesthetics, aiming to better address medical challenges and continuously enhance patient treatment experiences.
Mr. Zhang Chenchao, Founder of the CompanyStatement: With the rapid development of the domestic medical device industry, innovation and differentiation have become particularly crucial. The core advantage of active medical devices lies in their ability to rapidly translate cutting-edge technologies across disciplines, which not only enhances the application value of these technologies but also opens up new market spaces. Taking the company’s focus on irreversible electroporation (IRE) technology as an example, we have undertaken unique innovative efforts in the field of medical aesthetics by applying a technology traditionally used for tumor treatment to the treatment of skin lesions, significantly reducing tissue damage and the risk of side effects. This innovation reflects both the relentless efforts of our technical team and the company’s capability in cross-disciplinary technology application. We will continue to leverage our team’s innovation and execution capabilities to maintain a leading position in R&D and market expansion, committed to providing safer and more efficient solutions for patients and consumers.
Huayi Capital Investment Teamstated: “In recent years, irreversible electroporation (IRE) technology has achieved significant breakthroughs in fields such as oncology and arrhythmia management, fully validating its safety and efficacy. Shanghai Ounico Medical Technology Co., Ltd. pioneered the application of IRE technology in the medical aesthetics sector in China. This technology is non-thermal, thereby avoiding protein denaturation and tissue inflammation commonly associated with traditional treatments. It demonstrates a strong safety profile and therapeutic efficacy, making it suitable for treating conditions such as acne and skin warts, with potential expansion into areas like stretch mark treatment. We are optimistic about the technical sophistication and business acumen of the Ounico Medical team and look forward to their continued promotion of specialized innovation in high-end active medical aesthetic devices, leading industry development.”
Huayi Capital is a representative institution in China focused on quantitative evaluation and investment in the primary market for the healthcare and wellness industry. It has currently filed nine funds, with assets under management nearing RMB 8 billion. As a research-driven investment firm, Huayi Capital houses the Huayi Research Institute, the only medical investment research institute in China, and is recognized as the definer of the comprehensive landscape of medical investment in the country. Yiyun Technology serves as Huayi’s post-investment management platform, dedicated to profiling and evaluating Chinese healthcare and wellness enterprises using quantitative models.